Eli Lilly and Company
Anti-CD137 antibodies
Last updated:
Abstract:
The present invention relates to antibodies that bind to human CD137 and display agonist activity, and is useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
Status:
Grant
Type:
Utility
Filling date:
25 Jul 2018
Issue date:
2 Feb 2021